Global Innovative Platforms Announces Completion of First Phase of Breath Test Study for Early Heartworm Detection
Global Innovative Platforms (OTC: GIPL) completed the first phase of a breath-based diagnostic study for early detection of heartworm in dogs on Oct 7, 2025. The 12-month project collected and analyzed over 100 breath samples to validate markers that could enable a point-of-care, non-invasive test able to identify infection earlier than the current ~six-month detection window. The company plans further research to confirm breath markers and explore a proprietary device that could detect multiple conditions via a single breath analysis.
Global Innovative Platforms (OTC: GIPL) ha completato la prima fase di uno studio diagnostico basato sul respiro per l'individuazione precoce del heartworm nei cani il 7 ottobre 2025. Il progetto di 12 mesi ha raccolto e analizzato più di 100 campioni di respiro per validare marker che potrebbero consentire un test al punto di care, non invasivo, in grado di identificare l'infezione prima rispetto all'attuale finestra di rilevamento di circa sei mesi. L'azienda prevede ulteriori ricerche per confermare i marker del respiro ed esplorare un dispositivo proprietario che potrebbe rilevare molteplici condizioni tramite una singola analisi del respiro.
Global Innovative Platforms (OTC: GIPL) completó la primera fase de un estudio diagnóstico basado en la respiración para la detección temprana de la dirofilariasis en perros el 7 de octubre de 2025. El proyecto de 12 meses recopiló y analizó más de 100 muestras de aliento para validar marcadores que podrían permitir una prueba en el punto de atención, no invasiva, capaz de identificar la infección más temprano que la ventana de detección actual de alrededor de seis meses. La empresa planea más investigaciones para confirmar los marcadores de aliento y explorar un dispositivo propietario que podría detectar múltiples condiciones mediante un solo análisis de aliento.
Global Innovative Platforms (OTC: GIPL)는 2025년 10월 7일에 반려견의 심장사상충 조기 검사용 호흡 기반 진단 연구의 1단계를 완료했습니다. 12개월 프로젝트는 100건이 넘는 호흡 샘플을 수집·분석하여 현재 약 6개월의 발견 창보다 먼저 감염을 식별할 수 있는 현장 진단용 비침습 검사에 사용할 수 있는 마커를 검증했습니다. 회사는 호흡 표지자를 확인하고 단일 호흡 분석으로 여러 질병을 감지할 수 있는 독점 기기를 탐색하기 위한 추가 연구를 계획하고 있습니다.
Global Innovative Platforms (OTC: GIPL) a terminé la première phase d'une étude diagnostique basée sur l'haleine visant à la détection précoce de la dirofilariose chez les chiens le 7 octobre 2025. Le projet de 12 mois a collecté et analysé plus de 100 échantillons d'haleine afin de valider des marqueurs qui pourraient permettre un test au point de care, non invasif, capable d'identifier l'infection plus tôt que l'actuelle fenêtre de détection d'environ six mois. L'entreprise prévoit de poursuivre les recherches pour confirmer les marqueurs d'haleine et d'explorer un dispositif propriétaire qui pourrait détecter plusieurs conditions via une seule analyse de l'haleine.
Global Innovative Platforms (OTC: GIPL) hat die erste Phase einer auf Atem basierenden diagnostischen Studie zur frühzeitigen Erkennung von Herzbandwürmern (Herzwurmerkrankung) bei Hunden am 7. Oktober 2025 abgeschlossen. Das 12-monatige Projekt sammelte und analysierte mehr als 100 Atemproben, um Marker zu validieren, die einen punktgenauen, nicht-invasiven Test ermöglichen könnten, der die Infektion früher identifizieren kann als das derzeitige Detektionsfenster von etwa sechs Monaten. Das Unternehmen plant weitere Forschungen, um Atemmarker zu bestätigen, und prüft ein proprietäres Gerät, das über eine einzige Atemanalyse mehrere Zustände erkennen könnte.
Global Innovative Platforms (OTC: GIPL) أكملت المرحلة الأولى من دراسة تشخيصية تعتمد على التنفّس للكشف المبكر عن داء الدودة القلبية لدى الكلاب في 7 أكتوبر 2025. جمَع المشروع الذي امتد على 12 شهراً أكثر من 100 عينة تنفّس للتحقق من علامات قد تمكّن من اختبار في موقع الرعاية، غير جراحي، قادر على تحديد العدوى في وقت أبكر من نافذة الكشف الحالية التي تبلغ نحو ستة أشهر. تخطط الشركة لمزيد من الأبحاث لتأكيد علامات التنفّس واستكشاف جهاز مملوك يمكنه اكتشاف عدة حالات عبر تحليل تنفّس واحد.
Global Innovative Platforms (OTC: GIPL) 于 2025年10月7日 完成了犬类心虫早期检测的基于呼吸的诊断研究第一阶段。为期12个月的项目收集并分析了 超过100份呼吸样本，以验证可实现现场快速非侵入性检测的标志物，能够比当前大约六个月的检测窗口更早识别感染。公司计划进行进一步研究以确认呼吸标记，并探索一种专有设备，能够通过单次呼吸分析检测多种疾病。
- Completed first-phase study on Oct 7, 2025
- Collected and analyzed over 100 breath samples
- Study spanned a 12-month period
- Research aims to detect heartworm earlier than six months
- No efficacy readout or sensitivity/specificity figures disclosed
- No regulatory approvals or commercial device yet announced
- Further research required to confirm breath markers and device feasibility
New non-invasive diagnostic may identify heartworm months earlier than current methods
MAITLAND, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Global Innovative Platforms Inc. (OTC: GIPL) today announced completion of the first phase of its research into breath-based diagnostics for detecting heartworm disease in dogs. The initial study included over 100 samples and focused on validating data to support development of a point-of-care, non-invasive test designed to detect infection earlier than the current industry standard of six months.
“Early detection is the key to protecting dogs from the serious effects of heartworm,” said Andrew Brown, CEO of Global Innovative Platforms. “Our goal is to create a simple and non-invasive breath test that veterinary teams can use to potentially identify infections earlier than available heartworm diagnostic tests. If successful, earlier detection could enable veterinarians and owners the opportunity to intervene sooner, potentially helping dogs live healthier, longer lives.”
The American Heartworm Society currently recommends testing dogs beginning at six months of age and annually thereafter. At present, there is no point-of-care diagnostic widely available that can reliably identify heartworm infection until the infection has been present for approximately six months or more in that dog.
Dr. Lindsay Starkey, DVM, PhD, DACVM, who is leading the research team at Global Innovative, commented: “I am always looking for new ways to improve animal health. Working on this project is exciting, and the initial data is encouraging. We look forward to continuing the research and exploring how breath analysis may contribute to earlier, more effective detection. Dr. Starkey worked alongside Drs. Byron Blagburn and Sarah Zohdy, both of whom were pioneers in the initial heartworm breath research starting in 2017.
Additional on-site testing was overseen by parasitologist Dr. Elyssa Campbell, PhD. The twelve-month study period involved collecting and analyzing over 100 breath samples under her supervision. Dr. Campbell commented “I’m grateful to be working with such a talented team and committed to continuing this work. The data we have gathered show a lot of promise and reinforces our belief that breath analysis could be a significant step forward in veterinary diagnostics.”
Global Innovative is planning further research seeking to confirm heartworm breath markers and expand testing. If successful, the company may pursue development of a proprietary diagnostic device with the goal of allowing for it to have the potential to detect multiple conditions through a single breath analysis.
About Global Innovative Platforms Inc.
Global Innovative Platforms Inc. (OTC: GIPL) is focused on advancing animal health through non-invasive breath analysis and air quality technology. The Company’s Animal Health Division is developing diagnostic tools designed to detect disease, monitor treatment effectiveness, and assess environmental and food-related health risks.
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially, including but not limited to risks related to research and development outcomes, regulatory approvals, market acceptance, and other factors described in Global Innovative’s filings with the SEC. See the Company’s Annual Report Form 10-K for filed at www.sec.gov for other risk factors which investors should consider. These forward-looking statements speak only as to the date of this announcement and cannot be relied upon as a guide to future performance. Global Innovative expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any changes in its expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based.
Media Contact:
Andrew Brown, CEO
Andrew@GIPLinc.com
321.230.3739
FAQ
What did Global Innovative Platforms (GIPL) announce on October 7, 2025 about heartworm testing?
How many samples were used in GIPL's first-phase heartworm breath study?
Does GIPL's breath test currently detect heartworm earlier than six months?
What are GIPL's next steps after completing the first phase of the breath test study?
Will GIPL's breath analysis device detect conditions beyond heartworm?
